OnsiteGene

Executive Summary

OnsiteGene is a biotechnology company pioneering ultra-fast point-of-care nucleic acid testing, with its proprietary real-time PCR technology delivering results in as little as 5 minutes. Founded in 2019 and headquartered in San Diego, the company addresses critical time-to-result bottlenecks in life science research, industrial monitoring, and medical diagnostics. By enabling rapid, decentralized testing, OnsiteGene aims to transform workflows in settings where speed and accessibility are paramount, such as emergency rooms, field laboratories, and manufacturing quality control. The company's integrated platform—comprising instruments, kits, and reagents—is already commercialized in the US, Singapore, and China, positioning it for scalable growth. Despite being private and early-stage, OnsiteGene's technology fills a clear market gap, offering a compelling combination of speed, accuracy, and portability. The company's ability to secure regulatory approvals and strategic partnerships will be key to capturing share in the expanding point-of-care diagnostics market, projected to reach $50B by 2028.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance for First Diagnostic Test60% success
• H2 2026Strategic Partnership with Major Diagnostics Company40% success
• Q4 2026Series B Funding Round Closure70% success